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Abstract MicroRNAs (miRNAs) are a group of endogenous,
small (about 22 nucleotides) non-coding RNAs which nega-
tively regulate gene expressions. As one of them, miR-204
originates from the sixth intron of the transient receptor po-
tential melastatin 3 (TRPM3) gene. Therefore, expression of
miR-204 is under the control of the TRPM3 promoter and
regulated by genetic and epigenetic mechanisms. miR-204
has been found to play the important roles in development
of eyes and adipogenesis. Its pathological functions have been
observed in a few diseases including pulmonary arterial hy-
pertension, diabetes, and various types of cancers. It is be-
lieved that miR-204 acts as a tumor-suppressor via promoting
apoptosis, conferring the resistance of cancer cells to chemo-
therapy, and suppressing the self-renewal of cancer stem cells
(CSCs) and the epithelial to mesenchymal transition (EMT).
Expression of miR-204 is repressed by its targets XRN1 and
TRKB in prostate cancer and endometrial carcinoma, respec-
tively; therefore, they establish an oncogenic feedback loops
that play an important role promoting development of cancer.
In this review, we summarize our current knowledge regard-
ing miR-204, including its expression, regulation and biolog-
ical functions, especially focusing our discussion on its role in
tumor development and tumor progression.




ccRCC Clear cell renal cell carcinoma
CRPC Castration-resistant prostate cancer
CSCs Cancer stem cells
EEC Endometrioid endometrial cancer
EMT Epithelial to mesenchymal transition
VHL Hippel-Lindau tumor-suppressor gene
MSCs Mesenchymal stem cells
miRNAs MicroRNAs
NE Neuroendocrine
NEPC Neuroendocrine-like prostate cancer
NSCLC Non-small cell lung cancer
PDEF Prostate-derived Ets factor
RPE Retinal pigment epithelium
PAC Prostatic adenocarcinoma
SCNC Small-cell neuroendocrine carcinoma
SSCs Spermatogonial stem cells
TRPM3 Transient receptor potential melastatin 3 gene
TGF-β Transforming growth factor β
MicroRNAs (miRNAs) are a non-protein coding class of
small regulatory RNAs (22-nucleotides long) that play an es-
sential role in post-transcriptional regulation of gene expres-
sion through binding to the 3′-untranslated region (3´-UTR) of
messenger RNAs (mRNAs). The mechanism of mRNA si-
lencing depends on the degree of complementarity of the seed
sequence to the 3′-UTR of the target mRNA [1].When perfect
base-paring homology exists between amiRNA and amRNA,
the RNA-mediated interference pathway is induced, which
eventually results in cleavage of mRNA. When binding is
imperfect, which happens more commonly, the translation of
target mRNA is regulated without significantly affecting the
corresponding level of mRNA. On average, each miRNA
* Runsheng Li
runshengli2007@163.com
1 Key Laboratory of Reproduction Regulation of NPFPC, SIPPR,
IRD, Fudan University, Shanghai, China
Tumor Biol. (2016) 37:11667–11677
DOI 10.1007/s13277-016-5144-5
regulates approximately 200 target mRNAs and ~10–40 % of
the mRNA sequences are roughly estimated to be targeted by
microRNAs in human [2]. To date, over 2500 potential human
miRNAs have been recorded in miRBase v20 and the number
is still accumulating. miRNAs have been found to play inte-
gral roles in regulating an array of fundamental cellular pro-
cesses, including the cell cycle, differentiation, and prolifera-
tion, thereby adjusting numerous pathways related to devel-
opment and diseases.
To date, miR-204’s involvement has been demonstrated for
development of the retina and eye, diabetes, many types of
cancers, and other pathological processes. The present article
reviews our current knowledge of the physiopathology of
miR-204 with a focus on its function in different types of
cancers, particularly, in prostate cancer.
Physiological functions of miR-204
The role in development of eyes
Genes are known to have important functions in the tissues
where they are highly expressed. miR-204 is orders of mag-
nitude more highly expressed in human retinal pigment epi-
thelium (RPE) than in most of the 20 adult human tissues
tested [3] and highly expressed in eye of zebrafish and mouse.
miR-204 is one of miRNAs whose expression is regulated by
different levels of light in the mouse retina. In medaka fish,
Conte et al. reported that morpholino-mediated ablation of
miR-204 expression resulted in an abnormal phenotype of
eye which is associated with optic fissure coloboma [4].
Recently, by studying Dicer1-deficient RPE of mice, Ohana
et al. reported a key role of miR-204 in regulation of the RPE
differentiation program. These reports, therefore, highlight
miR-204 as a Bmaster regulator^ of the molecular networks
that regulates lens morphogenesis in vertebrates.
miR-204 acts as the master regulator in the model of
medaka fish, and the transcription factor MEIS2 is one of
the main targets of miR-204 functions [4]. MEIS2
homeoprotein directly upregulates PAX6 [5], a lineage-
specific transcriptional factor that plays a key role during
vertebrate lens morphogenesis. In turn, PAX6 was shown
to promote expression of miR-204 both in mice and in
medaka by directly binding its promoter [6]. In addition
to MEIS2, other genes including SOX11, an important
factor for development of eye and the central nervous
system, were also shown to be the miR-204 targets in
RPE. Importantly, these miR-204 targets (e.g., SOX11,
etc.) are upregulated in the lens with knockout of PAX6,
suggesting that PAX6 downregulates multiple genes dur-
ing eye development in the way dependent on miR-204
[6]. Together, these results strongly suggest the presence
of a miR-204-MEIS2-PAX6 negative feedback loop in
RPE which controls the physiological function of miR-
204 in eye development.
The role in adipogenesis
Mesenchymal stem cells (MSCs) have potential to undergo
multilineage differentiation into multiple connective tissue
cell types, such as osteoblasts, adipocytes, and myoblasts.
Differentiation of MSCs into different lineages of cells is
tightly regulated, and alteration or malfunction of this regula-
tion could result in pathological consequences. For example,
bone loss is often accompanied with the increase of bone
marrow adiposity in aging [7]. Moreover, it was reported that
adipose tissue in bone marrow is inversely related to bone
formation in osteoporosis, and patients with high bone mass
phenotype show inhibition of adipogenesis [8]. These findings
suggest a switch between the osteoblast and the adipocyte
differentiation of the MSCs during the development of osteo-
porosis or a high bone mass phenotype. Interestingly, miR-
204 promotes the adipogenesis and inhibits the osteogenesis
of human MSCs through the direct suppression of RUNX2
[9], a key transcription factor for osteogenesis. Therefore,
miR-204 is a Bswitch^ molecule that controls the fate choice
between osteogenesis and adipogenesis [9]. Consistently,
miR-204 promotes the differentiation of human adipose-
derivedMSCs into mature adipoctyes [10]. Moreover, dishev-
eled segment polarity protein 3 (DVL3), a key regulator of the
Wnt/β-catenin signaling pathway, was identified as the
target of miR-204. In addition, overexpression of miR-
204 was shown to induce the downregulation of β-
catenin and the canonical Wnt target gene, CCND1, in
mature adipoctyes, while its knockdown led to upregu-
lation of CCND1. Therefore, miR-204 was proposed to
regulate adipogenesis by controlling DVL3 expression
and subsequently inhibiting the activation of the Wnt/
β-catenin signaling pathway [10].
Pathological studies have uncovered that downregula-
tion of miR-204 contributes to enhanced proliferation and
reduced apoptosis of pulmonary artery smooth muscle
cells [11], which eventually resulted in pulmonary arterial
hypertension (PAH). In addition, miR-204 plays a critical
role in development of diabetes. For instance, beta-cell
dysfunction and impaired insulin production are hall-
marks of diabetes. Beta-cell thioredoxin-interacting pro-
tein (TXNIP), a cellular redox regulator upregulated in
diabetes, induces the expression of miR-204. By targeting
and downregulating MAFA, a known insulin transcription
factor, miR-204, blocks insulin production [12]. In con-
trast, TXNIP deficiency protects against diabetes by
preventing beta-cell apoptosis [12]. These results demon-
strated a potential anti-apoptotic role of miR-204 in beta
cells.
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Roles of miR-204 in cancers
To date, most of researches regarding miR-204 have been
focused on its roles in cancers. Studies have demonstrated that
miR-204 has a dual function as a tumor-suppressive gene and/
or an oncomiR in different cancers.
Aberrant expression of miR-204 in cancers
The first study regarding miR-204 in cancers was reported by
Rolda et al. in 2007, who observed that miR-204 is dramati-
cally upregulated in insulinomas and that its expression level
correlates with immunohistochemical expression of insulin
[13]. Subsequently, it was shown that miR-204 is one of five
miRNAs that most highly expressed in acute lymphocytic
leukemias [14]. However, in contrast to these reports, de-
creased miR-204 was shown in many solid tumors, including
primary melanomas glioma, non-small cell lung cancer, blad-
der cancer, gastric cancer, head and neck tumor, and
endometrioid endometrial cancer (EEC) [15–18]. However,
there are conflicting results regarding the miR-204 expression
in some other solid tumors including breast cancer and pros-
tate cancer (PCa). For example, while miR-204 expression
was shown to be significantly elevated in five human breast
tumors when compared to their matched adjacent non-tumor
samples [19], other studies showed the opposite results indi-
cating that not only are miR-204 expression in breast cancer
specimens lower than that in their adjacent normal tissues but
also the low expression of miRNA is significantly associated
with a more aggressive tumor phenotype [20, 21]. Similarly,
in PCa, an increased expression of miR-204 was previously
observed in five tumor specimens by immunostaining [22]. In
contrast to this, by analyzing a tissue microarray that included
135 PCa specimens, we showed that lower levels of miR-204
in primary prostate cancer than that in the control samples
[23]. Moreover, we demonstrated an inverse correlation be-
tween and miR-204 in prostate cancer specimens and serum
level of prostate-specific antigen (PSA), which is an important
clinical diagnostic biomarker of PCa [23].
Tumor-suppressive role of miR-204
Although function of miR-204 has not yet been reported in
insulinomas and acute lymphocytic leukemias where it is
highly expressed [13, 14], most of studies have revealed that
miR-204 plays a role as a tumor-suppressive gene in all types
of cancers studied. To explore its anticancer mechanism, re-
searchers have reported 30 validated target genes of miR-204
in different cultured cells representing 19 types of cancers
(Table 1). Among these target genes, the expression of
BDNF [20], MEIS1 [38], FOXC1 [18], NUAK1 [40],
RAB22A [42], and XRN1 [23] is inversely correlated with
that of miR-204 in those tumor specimens examined, strongly
suggesting that miR-204 is one of the key suppressors of the
target genes. Accumulating evidence has recently demonstrat-
ed that long non-coding RNAs (lncRNAs) play a pivotal role
in tumorigenesis. miR-204 was also shown to repress
LncRNA HOTTIP expression via the argonaute 2-mediated
RNA interference pathway in hepatocellular carcinoma [37].
This study is particularly interesting, since it provides an ex-
ample to show how expression of lncRNAs is controlled by
short ncRNAs, such as miR-204.
Table 1 Target genes of miR-204 validated in cancer cells
Target gene Types of cancer/cells Ref.




BDNF Breast cancer [20]
CDC42 Nasopharayngeal carcinoma [28]
CYCLIN D2 Retinoblastoma [29]
EPHB2 Glioma [30]
EZRIN Gastric cancer [31]
FOXC1 Endometrial cancer [18]
FOXM1 Cholangiocarcinoma [32]
IGFBP5 Papillary thyroid carcinoma [33]
IL-11 Breast cancer [34]
JAK2 Breast cancer [35]
LC3B Clear cell renal cell carcinoma [36]
LncRNA HOTTIP Hepatocellular carcinoma [37]
MEIS1 Nephroblastomas [38]
MCL-1 Pancreatic cancer [39]
MMP-9 Retinoblastoma [29]
NUAK1 Non-small cell lung cancer [40]
PDEF Prostate cancer [22]
Breast cancer [19]
PHOX2B Neuroblastoma [41]
RAB22A Colorectal cancer [42]
Gastric cancer [43]
RUNX2 Prostate cancer [44]
SIRT1 Gastric cancer [45]
SIX1 Non-small cell lung cancer [16]
Breast cancer [46]
SAM68 Breast cancer [47]
SLUG Intrahepatic cholangiocarcinoma [48]
SOX4 Glioma [30]
Gastric cancer [49]
Squamous cell carcinomas [50]
TRKB Neuroblastoma [40]
TRPM3 Clear cell renal cellcarcinoma [51]
USP47 Gastric cancer [43]
XRN1 Prostate cancer [23]
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Alterations in the apoptotic response in cancer cells can
promote tumor initiation, progression, and drug resistance.
Apoptosis can be triggered by different signals such as DNA
damage, upon which activation of p53 protein promotes apo-
ptosis through upregulating the transcription of several pro-
apoptotic proteins in BCL-2 family members. On the other
hand, by sequestering these pro-apoptotic BCL-2 family
members and thereby inhibiting their pro-apoptotic activities,
BCL-2 exerts its anti-apoptotic function [52]. Several studies
have demonstrated that some oncogenic miRNAs are in-
volved in the control of apoptosis and exert their anti-
apoptotic effects by directly targeting pro-apoptotic BCL-2
members’ mRNAs [53]. BCL-2 has been observed to be the
miR-204 target in four types of cancers in vitro (Table 1).
Therefore, induction of apoptosis seems to be the common
mechanism for tumor-suppressive role of miR-204.
However, none of the studies thus far revealed the presence
of inverse correlation between expression of BCL-2 and miR-
204 [24–27]. Given that a mechanism blocking the binding of
miR-204 to 3′-UTR of BCL-2 was recently proposed [54]
(also shown later), a further study is needed to confirm that
miR-204 is actually the key regulator of BCL-2 in vivo.
EMT is a unique process that describes the molecular
reprogramming and phenotypic changes characterized by
a transition from polarized immotile epithelial cells to
motile mesenchymal cells, leading to tumor metastases.
This transition is often associated with a decrease in the
expression of proteins that enhance cell-cell contact (e.g.,
E-cadherin and γ-catenin, etc.), as well as with an in-
crease in the expression of mesenchymal markers (e.g.,
vimentin and N-cadherin, etc). Transforming growth fac-
tor β (TGF-β) is a critical factor which induces EMT and
has a key role in the bone metastatic process of breast
cancer cells. In the bone microenvironment, TGF-β is
released from bone during bone resorption, then it stimu-
lates breast cancer cells to produce osteolytic factors such
as interleukin 11(IL-11) to mediate osteolysis by stimulat-
ing osteoclast formation and bone resorption activity [55].
Additionally, TGF-β stimulates expression of master
EMT regulators, such as SOX4 and members of the
Twis t , Sna i l f ami l i e s o f t r ansc r ip t ion fac to r s .
Overexpression of homeoprotein SIX1, a developmentally
restricted transcriptional regulator, induces EMT that is in
part dependent on its ability to increase TGF-beta signal-
ing [56]. Interestingly, IL-11 [34], SOX4 [49] and SIX1
[16] have been shown to be the targets of miR-204.
Therefore, by repressing the expression of these genes,
miR-204 exerts its tumor-suppressive effect via inhibiting
EMT and bone metastasis of breast cancer cells [20].
Consistent with this, systemic delivery of miR-204 using
a lipid-based vehicle resulted in significant reduction or
elimination of lung metastases in a mouse model [20].
These results also revealed the potential of miR-204-
based strategy for cancer treatment. In addition to sup-
pressing breast cancer, miR-204 also represses EMT and
metastasis of other cancer cells. For example, miR-204
inhibits invasion and EMT phenotype of esophageal can-
cer cells through targeting forkhead box protein M1
(FOXM1) gene [32], a transcription factor which plays
an important role in the activation of EMT. SIRT1, a class
III histone deacetylase, is upregulated in lymph node me-
tastases of gastric cancer. By targeting SIRT1, overexpres-
sion of miR-204 decreases the levels of EMT-associated
gene vimentin but increases E-cadherin levels in gastric
cancer cells [45]. Consistent with this, miR-204 signifi-
cantly suppresses lung metastasis of NSCLC cancer cells
in a SCID mouse model [40].
A relationship between EMTand cancer stem cells (CSCs)
has been proposed with evidence demonstrating that EMT
cells exhibit stem cell-like traits and CSCs acquire
mesenchymal-like characteristics [57]. CSCs, similar to so-
matic stem cells, are defined as cells within a tumor that pos-
sess the capacity to self-renew and to differentiate into the
heterogeneous lineages of cancer cells that comprise the tu-
mors [57]. CSCs have a great impact on development of tu-
mors including tumor growth, metastasis, and recurrence due
to their self-renewal potential and multidirectional differenti-
ation ability. The 68-kDa Src-associated protein in mitosis
(SAM68) is a GTPase-activating protein (GAP)-related pro-
tein involved in intracellular signal transduction that maintains
the self-renewal of breast CSCs via affecting the oncogene
serine/arginine-rich splicing factor. By targeting SAM68,
miR-204 reduces the stem cell phenotype in breast cancer
and neutralizes the tumorigenic effect of Sam68 in vivo
[47]. It was also reported that miR-204 suppresses self-renew-
al, stem cell-associated phenotype, and migration of glioma
cells via targeting the stemness-governing transcriptional fac-
tor SOX4 and the migration-promoting receptor EphB2 [30].
Together, these results suggest that miR-204 acts as a tumor-
suppressive gene in CSCs.
Tumor-suppressive activity of miR-204 has been reflected
by its promoting effect on chemotherapy of cancer cells as
well. It was shown that overexpression of miR-204 increases
responsiveness of gastric cancer cells to 5-fluorouracil and
oxaliplatin treatment [27]. miR-204 also inhibits proliferation
and invasion and enhances chemotherapeutic sensitivity of
colorectal cancer cells by downregulating RAB22A [42].
Moreover, ectopic miR-204 expression significantly increases
sensitivity of neuroblastoma cells to cisplatin and etoposide
in vitro [26].
Dual regulatory function of miR-204 in prostate cancer
Prostate cancer (PCa) is the most common malignancy affect-
ing males in western countries, and it is the second leading
cause of cancer deaths worldwide. Tremendous studies have
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proven that androgen, which works by binding and activating
androgen receptor (AR), is critical for progression of prostate
cancer [58]. Androgen deprivation treatment (ADT) has been
used clinically to suppress the tumor growth and progression
of androgen-sensitive prostate cancer. However, 2–3 years af-
ter treatment, many androgen-sensitive prostate cancers will
eventually develop the resistance to ADT and become
castration-resistant prostate cancer (CRPC), in which upregu-
lation of androgen signaling pathway is believed to play an
important role [58, 59].
Vast majority of PCa is characterized as prostatic adeno-
carcinoma (PAC) with luminal cell features and expression
of AR and PSA [58]. Interestingly, PAC usually contains a
small population (usually ~1 %) of scattered neuroendo-
crine (NE)-like prostate cancer (NEPC) cells that do not
express AR and PSA [60] (Fig. 1). As a subtype of NEPC
cells, small cell neuroendocrine carcinoma (SCNC) is often
seen in patients with advanced disease and is composed of
pure neuroendocrine tumor cells that express prostate CD44
[61], a marker of CSCs. NE differentiation (NED) of PAC
cells to NEPC can be induced in cultured cells. For example,
treatment of LNCaP cells, the most widely used PAC cell
line, with cAMP (or cAMP-inducing agents) or androgen
depletion induces NED within a few days [62]. Importantly,
studies have shown that ADT may contribute to develop-
ment of CRPC [63], in which the focal NED within the
tumors increases the levels of NE-derived peptides such as
neuron-specific enolase, leading to increased levels of
chromogranin-A in patient serum [63]. Consistent with this,
studies indicated that suppression of AR expression is re-
quired for NED of cultured PAC cells in vitro [64]. It is
believed that cancerous NE cells secrete a variety of growth
factors that can promote the proliferation of adjacent PAC
cells through a paracrine mechanism in an androgen-ablated
environment [65], accounting for androgen-independent
growth of prostate cancer (Fig. 1). Therefore, it was pro-
posed that AR can be either tumor suppressor or promoter
in prostate cancer [66], depending on the pathological
background.
The role of miR-204 in PCa was first reported by Turner
et al., who identified that prostate-derived Ets factor (PDEF)
is a target of miR-204 [22]. Given that overexpression of
PDEF repressed growth of prostate cancer DU-145 cell line
and PC-3 cell line, which represents the NEPC cells, and
that the expression of PDEF in prostate cancer specimens is
downregulated when compared with the controls [22], it
suggests that miR-204 is an oncomiR through targeting
PDEF and inhibiting PDEF’s tumor-suppressive function
in PCa.
By using comprehensive approaches including gain/lost of
function of miR-204 and xenografts analyses, we demonstrat-
ed that miR-204 acts as an oncomiR in NEPC cells (PC-3 cells
and CL1 cells) but as a tumor suppressor in PAC cells
including LNCaP cells and 22RV1 cells [23] (Fig. 2). We
identified that XRN1, 5′-3’exoribonuclease 1, is a miR-204
target. XRN1, as well as the other members of the highly
conserved XRN1 family, degrade diverse RNA substrates dur-
ing general RNA decay and function in specialized processes
of RNA metabolism, such as nonsense-mediated decay, gene
silencing, rRNA maturation, and transcription termination
[67]. Interestingly, knockdown of XRN1 also dually regulated
cell growth and colony-forming capability of NEPC and PAC
cells, consistent with effects of ectopic expression of miR-204
in these PCa cell lines [23]. The dual regulatory function of
miR-204/XRN1 was further demonstrated by their dually-
modulating effects on expression of some key regulators of
cell cycle and apoptosis, including AKT phosphorylation,
Cyclin D1, and p21WAF1 (Fig. 2). In addition, we further re-
vealed that androgen/AR inhibits the expression of miR-204
both in PAC cells and NEPC cells, subsequently leading to
upregulation of XRN1 expression in a way depending on
suppression of miR-204 [23]. Therefore, AR-miR-204-
XRN1 axis is probably one of the key mechanisms for dual
regulatory function of AR in different stages of tumor progres-
sion of PCa.
AR has also a dual regulatory function in breast cancer
cells [68]. Although most studies suggested that miR-204
is a tumor suppressor in breast cancer [20, 21, 69, 46],
overexpression of miR-204 was also shown to increase
migration, invasion, and metastasis of breast cancer
MCF-7 cells and inhibit EMT by targeting PDEF [19].
Given that miR-204 is downregulated by androgen in
MCF-7 cells (our unpublished data), it will worth exam-
ining whether the above conflicting results are caused by
varied AR backgrounds in different breast cells tested.
Besides XRN1, cdc42 is another miR-204 target [28]
which has a dual yet opposite growth-regulatory function in
cancer cells [70]. It is currently unknown whether cdc42 has a
contribution to miR-204-mediated dual function in cancer
cells.
Factors regulating expression and function
of miR-204
Hereditary factor
High-resolution custom miRNA comparative genomic hy-
bridization (CGH) of public domain datasets for several types
of cancers showed that the 9q21.12 chromosomal region con-
taining miR-204 is frequently lost in multiple types of cancers
[20, 71], suggesting that loss of genomic loci containing miR-
204 is directly linked with the deregulation of key tumor-
suppressive pathways, leading to tumor growth and
metastasis.
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By binding to the 3′-UTR of target genes, miRNAs
exert their expression-regulating rule. However, the inter-
action can be significantly affected by SNP either in miR-
204 or in the 3′-UTR of targets. Recently, a new hetero-
zygous mutation, n.37 C > T, in the seed region of miR-
204 was identified in a five-generation family of an auto-
somal dominantly inherited condition of retinal dystrophy
and bilateral coloboma [72]. Consequently, this mutation
significantly alters miR-204’s targeting capabilities.
In vivo injection of this mutated miR-204 in medaka fish
caused a phenotype consistent with that observed in the
family. This provides the first evidence of miR-204’s con-
tribution to eye disease, likely through a gain-of-function
mechanism. On the other hand, the SNPs in 3′-UTR of
PHOX2B differentially affect miRNA-mediated regula-
tion of the stability of target mRNAs [41].
Factor blocking binding of miR-204 to 3′-UTR of its
targets
Besides some SNPs, human transformer 2β (TRA2β) has
been recently reported to affect interaction of miR-204 and
its target by competing the binding sequence of miR-204 in
a mutually exclusive way [54]. TRA2β is a serine/arginine-
rich-like protein splicing factor with wide-ranging roles in
gene expression as an RNA-binding protein. The consensus
sequence for TRA2β-binding (GAA) lies within the miR-
204-binding site of BCL-2 3′-UTR, TRA2β antagonizes the
effects of miR-204 and upregulates BCL-2 expression [54].
Such a mechanism is very interesting, partially because it can
explain why miR-204 regulates expression of its targets with
different efficiencies in the way depending on cell lines used
[44]. Given that TRA2β mRNA expression is significantly
upregulated in colon cancer [54] and prostate cancer tissues
compared with paired normal tissues, it is highly possible that
TRA2β plays an important role in carcinogenesis by blocking
function of miR-204.
miR-204 and TRPM3
TRPM3 gene encodes proteins that form cation-permeable ion
channels on the plasma membrane. The miR-204-encoding
gene is located in the sixth intron of TRPM3. Expression of
mature miR-204 and pri-miR-204 linearly correlated with that
of TRPM3 gene both in vitro [11, 30] and in vivo [23], strong-
ly suggesting that miR-204 and TRPM3 share common regu-
latory mechanisms. Downregulation of miR-204 in glioma
[30] and NSCLC [40] was attributable to the DNA methyla-
tion of TRPM3 promoter.
Interestingly, TRPM3 was validated to be a target of miR-
204 [51], consistent with that some genes are autoregulated
via intronic microRNAs [73]. Some stimuli may induce ex-
pression of both miR-204 and TRPM3. The activity of miR-
204 would then contribute to downregulation of TRPM3 ac-
tivity to the pre-stimulus level. Therefore, both TRPM3 and
miR-204 can play their roles only temporarily in these circum-
stances. With the role of TRPM3 in cancers [51, 74], the
TRPM3-miR-204 feedback loop may be important to prevent
progression of oncogenic transformation and may also exist
widely in physiological situations.
TRPM3 is overexpressed in choroid plexus papillomas,
glioblastoma multiforme, and clear cell renal cellcarcinoma
(ccRCC) [51, 74], suggesting that TRPM3 has a tumor-
promoting role. It is currently unknown whether miR-204
expression actually increases as a result of TRPM3 overex-
pression in choroid plexus papillomas and glioblastoma
Fig. 1 Neuroendocrine differentiation promotes recurrence of prostate
cancer. The cultured PAC cells can be induced to differentiate into
NEPC cells by diverse signals including cAMP, IL-6 and androgen de-
pletion via different mechanisms. Most of PAC cells die in the patients
who are treated with androgen deprivation treatment (ADT). However,
ADT also causes NED. The NEPC cells secret multiple neuropeptides
which promote survival and growth of PAC cells in the presence of ADT.
The recurrence is eventually
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multiforme. ccRCC is a dominant subtype of kidney cancers
in most of which the von Hippel-Lindau (VHL) tumor-
suppressor gene is mutated or lost [75]. The tumor-
suppressive function of VHL gene depends on its promoting
effect on miR-204 expression [36]. Interestingly, VHL-
induced expression of miR-204 correlated with expression
of two short transcripts from TRPM3, but with not expres-
sion of the large transcript encoding the full-length protein
[36]. Uncoupling of expression of TRPM3 and miR-204 is
obviously important for development of ccRCC and proba-
bly exists in other types of cancers where TRPM3 is
upregulated.
Fig. 2 miR-204 and its target XRN1 dually regulate growth of different
prostate cancer cells. a and b Cell growth of different PCa cell lines
infected with the recombinant miR-204-expressing lentivirus or the con-
trol lentivirus. c Effect of silencing of XRN1 on cell growth. d Western
blot analysis of prostate cancer cells transfected with XRN1 siRNA. eRT-
qPCR assays of four AR-targeting miRNAs in LNCaP. f Schematic rep-
resentation of the proposed AR/miR-204/XRN1/miR-34a feedback loop.
The activation of the loop by androgen induces an upregulation of AR
signaling. Themodulation is advantageous for development of aggressive
phenotype of PAC. Cited from Ding et al. [23]
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Transcriptional repressor of miR-204
The signal transducer and activator of transcription (STAT)-3
plays an indispensable role in the progression of a wide variety
of cancers. Activation of STAT3 is mediated by phosphoryla-
tion of latent cytoplasmic STAT3 on specific residues (Y705,
Ser727) by a variety of tyrosine and serine kinases (e.g., Src
and JAK2), leading to its dimerization and nuclear transloca-
tion, where STAT3 acts as a transcription factor to modulate
expression of different genes including miRNA-204. The ac-
tivated STAT3 binds preferentially the TRPM3 promoter,
eventually suppresses expression of miR-204 in pulmonary
artery smooth muscle cells [11, 76]. Moreover, exosomes-
mediated cytoprotective action of mesenchymal stromal cells
induced by hypoxia-induced pulmonary hypertension de-
pends on inhibition of STAT3-miR-204 axis [77]. Similarly,
activation of STAT3 has been shown to downregulate miR-
204 expression in nasopharayngeal carcinoma [28] and endo-
metrial carcinoma [78]. Given that STAT3 is a critical media-
tor of differentiation, activation, migration, and inflammatory
capacity of immune cells and stromal cells that create the
microenvironment supporting tumor cell growth [79], it will
not be surprising that miR-204 has multiple functions in can-
cer development.
Positive feedback loops of miR-204 and its targets
As already observed in other miRNAs, expression of miR-204
is also regulated by its targets. The miR-204-Meis2-Pax6 neg-
ative feedback loop as mentioned above plays an important
role in eye development. However, three other positive feed-
back loops between miR-204 and its different targets have
been established. For examples, miR-204 and its target Six1
inhibit their expression mutually [46]. TrkB-STAT3-miR-204
regulatory circuitry plays an important role in promoting me-
tastasis in endometrial carcinoma [78]. In this loop,
tropomyosin-related kinase B (TRKB), a miR-204 target
[40], activates the JAK2/STAT3, and further suppresses ex-
pression of miR-204, eventually resulting in an increased ex-
pression of miR-204 targets including TRKB itself [78].
TRKB, which is important for neural development and is an
independent prognostic marker in many tumor types, is the
receptor of brain-derived neurotrophic factor (BDNF) [80].
Given that BDNF is also a miR-204 target [20], the above
loop is expanded to BNDF-TrkB-STAT3-miR-204 regulatory
circuitry. However, its significance is needed to be further
evaluated in different models of cancers.
Recently, we identified an AR-miR-204-XRN1-miR-34a
regulatory circuitry in prostate cancer cells [23]. In this loop,
AR signal represses miR-204 expression, increasing protein
levels of XRN1, which then degrades miR-34a in a cell type-
dependent way [23] (Fig. 2). Moreover, AR itself is a target of
miR-34a as reported previously, AR signaling is therefore
much enhanced in prostate cancer cells through this loop
(Fig. 2). Interestingly, both of regulatory circuitries (i.e.,
BNDF-TrkB-STAT3-miR-204 and AR-miR-204-XRN1-
miR-34a circuitries) establish themechanism bywhich a weak
signal generates a strong effect. Such a mechanism could
make a great contribution to development and recurrence of
cancers.
Perspectives
Given the abundant literature, it is now increasingly clear that
miR-204 is a tumor-suppressive gene. However, its function
can also evolve towards to an oncomiR in some situations, for
example, under pressure of therapy in PCa. This is a challenge
for miR-204-based cancer therapies. It is expected that miR-
204 also plays an important function in early development of
mammalian embryos, given the reported establishment of
miR-204 functions in different stem cells. Additionally,
miR-204 and miR-211 have the same seed-region sequence
and, therefore, have theoretically the same targets. Although
miR-211 is expressed at a very low level compared with miR-
204 in most tissues, it is expressed at a higher level than miR-
204 in melanocytes, suggesting a more dominant function in
melanogenesis [3]. A high level of miR-211 can interfere with
the significance of downregulation of miR-204 in progression
of cancer. In future studies, it would be of interest to distin-
guish the different expression patterns and the functional ac-
tivities of miR-204/211.
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